98%
921
2 minutes
20
Subcortical neuromodulatory activity in the mammalian brain enables flexible wake behaviors, which are essential for survival in an ever-changing external environment. With the suppression of such behaviors in sleep, this activity is, on average, much reduced. Recent discoveries, enabled by unprecedented technical advancements, challenge the long-standing view that monoaminergic systems-noradrenaline (NA), dopamine (DA), and serotonin (5-HT)-remain largely inactive during sleep. This review highlights recent technological and scientific progress in this field, summarizing evidence that monoaminergic signaling in the brain supplements sleep with essential wake-related functions. Stress and/or neuropsychiatric conditions negatively impact on monoaminergic signaling, which can lead to sleep disruptions. Furthermore, subcortical neuromodulatory systems are vulnerable to neurodegenerative pathologies, which implies them in sleep disruptions at early stages of disease. We propose that future research will be well-invested in elucidating the spatiotemporal organization, cellular mechanisms, and functional relevance of neuromodulatory dynamics across species, and in identifying the molecular and physiological processes that sustain their integrity throughout the lifespan.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.conb.2025.103025 | DOI Listing |
Front Nutr
August 2025
Faculty of Medicine, Department of Psychiatry, Medical University of Gdańsk, Gdańsk, Poland.
Unlabelled: Mood disorders, including major depressive disorder (MDD) and bipolar disorder (BP), significantly impact global health, with MDD affecting over 300 million people and BP affecting approximately 2% of the world's population. Ketamine, originally an anesthetic, has emerged as a promising treatment for patients with treatment-resistant depression (TRD), due to its unique pharmacological properties, such as N-methyl-D-aspartate (NMDA) receptor antagonism and anti-inflammatory effects. The potential of ketamine in treating depression has sparked debate regarding its effects on appetite.
View Article and Find Full Text PDFMol Psychiatry
August 2025
Institute of Experimental Pharmacology and Toxicology, Center of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia.
When accompanied by excessive exposure to the stressors, pregnancy may result in prenatal depression, that has in turn negative influence on the offspring's brain. Mirtazapine, among other antidepressants, is commonly used to treat prenatal depression. Even though mirtazapine is generally considered safe for pregnant women, its effect on the offspring brain have not been sufficiently investigated.
View Article and Find Full Text PDFPharmacol Res
August 2025
Goethe University Frankfurt, University Hospital, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Frankfurt, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, Frankfurt am Main 60596, Germany.
Treatment-resistant depression (TRD) represents a major clinical challenge. Affecting about 30 % of major depressive disorder (MDD) patients, effective treatments for TRD are urgently needed. While depression research and antidepressant (AD) development have long centred on monoaminergic targets, research over the past 35 years has increasingly explored glutamatergic mechanisms.
View Article and Find Full Text PDFBiomed Pharmacother
August 2025
Department of Psychiatry, The Fourth People's Hospital of Nantong, Nantong, Jiangsu 226000, China. Electronic address:
Current commercial antidepressants worldwide are mainly developed according to the monoaminergic hypothesis of depression and have various limitations. Thus, exploring new antidepressants with better therapeutic efficacy and fewer adverse effects remain a hot topic in the field of neuropsychiatric research. Peroxisome proliferator-activated receptors (PPARs) have been demonstrated to closely participate in the pathophysiology of depression, and here we assume that lanifibranor, a novel pan-PPAR agonist for α, δ, and γ, may induce antidepressant-like actions by PPARs activation.
View Article and Find Full Text PDFBrain Struct Funct
August 2025
Department of Social Psychology and Quantitative Psychology, Institute of Neurosciences, University of Barcelona, Bellvitge Biomedical Research Institute (IDIBELL) and CIBERSAM, Barcelona, Spain.
Monoaminergic systems, including serotonin, dopamine, and norepinephrine, are essential for regulating brain activity and facilitating behavioral flexibility. These systems originate from brainstem nuclei and project widely to modulate functions such as mood, attention, memory, and adaptability. Using resting-state functional MRI (rs-fMRI), this study aimed to investigate the connectivity networks of key monoaminergic nuclei in 193 healthy adults and explore their correspondence with molecular imaging maps of neurotransmitter-specific biochemical markers.
View Article and Find Full Text PDF